Orchestra BioMed Holdings Profit Margin

Orchestra BioMed Holdings posts a profit margin of -185.4% as of June 2026. That compares with -2367.49% in the prior-year period — up 92.2% year over year. That is below the sector sector average of 22.52%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Orchestra BioMed Holdings's profit margin was -2367.49%. The latest reading is -185.4% — a 92.2% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 22.52% is typical. Orchestra BioMed Holdings's -185.4% is lower that level. That is roughly 923.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Orchestra BioMed Holdings's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -185.4% as of June 2026; use YoY and peer views to separate noise from signal.

Context for OBIO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.52%), and (3) consistency with growth and profitability. This page covers the first two; Orchestra BioMed Holdings's other metric pages and overview cover the third.